» Articles » PMID: 23029232

Immunization with M2e-displaying T7 Bacteriophage Nanoparticles Protects Against Influenza A Virus Challenge

Overview
Journal PLoS One
Date 2012 Oct 3
PMID 23029232
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Considering the emergence of highly pathogenic influenza viruses and threat of worldwide pandemics, there is an urgent need to develop broadly-protective influenza vaccines. In this study, we demonstrate the potential of T7 bacteriophage-based nanoparticles with genetically fused ectodomain of influenza A virus M2 protein (T7-M2e) as a candidate universal flu vaccine. Immunization of mice with non-adjuvanted T7-M2e elicited M2e-specific serum antibody responses that were similar in magnitude to those elicited by M2e peptide administered in Freund's adjuvant. Comparable IgG responses directed against T7 phage capsomers were induced following vaccination with wild type T7 or T7-M2e. T7-M2e immunization induced balanced amounts of IgG(1) and IgG(2a) antibodies and these antibodies specifically recognized native M2 on the surface of influenza A virus-infected mammalian cells. The frequency of IFN-γ-secreting T cells induced by T7-M2e nanoparticles was comparable to those elicited by M2e peptide emulsified in Freund's adjuvant. Emulsification of T7-M2e nanoparticles in Freund's adjuvant, however, induced a significantly stronger T cell response. Furthermore, T7-M2e-immunized mice were protected against lethal challenge with an H1N1 or an H3N2 virus, implying the induction of hetero-subtypic immunity in our mouse model. T7-M2e-immunized mice displayed considerable weight loss and had significantly reduced viral load in their lungs compared to controls. We conclude that display of M2e on the surface of T7 phage nanoparticles offers an efficient and economical opportunity to induce cross-protective M2e-based immunity against influenza A.

Citing Articles

Designing a multi-epitope influenza vaccine: an immunoinformatics approach.

Momajadi L, Khanahmad H, Mahnam K Sci Rep. 2024; 14(1):25382.

PMID: 39455641 PMC: 11512060. DOI: 10.1038/s41598-024-74438-w.


Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.

Ren M, Abdullah S, Pei C, Guo H, Sun S Vet Res. 2024; 55(1):128.

PMID: 39350170 PMC: 11443892. DOI: 10.1186/s13567-024-01383-x.


A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.

Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y Antibiotics (Basel). 2024; 13(9).

PMID: 39335043 PMC: 11428490. DOI: 10.3390/antibiotics13090870.


Phage based vaccine: A novel strategy in prevention and treatment.

Hasani S, Ghafouri E, Kouhpayeh S, Amerizadeh F, Rahimmanesh I, Amirkhani Z Heliyon. 2023; 9(9):e19925.

PMID: 37809683 PMC: 10559356. DOI: 10.1016/j.heliyon.2023.e19925.


SpyTag/SpyCatcher display of influenza M2e peptide on norovirus-like particle provides stronger immunization than direct genetic fusion.

Lampinen V, Grohn S, Soppela S, Blazevic V, Hytonen V, Hankaniemi M Front Cell Infect Microbiol. 2023; 13:1216364.

PMID: 37424789 PMC: 10323135. DOI: 10.3389/fcimb.2023.1216364.


References
1.
Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L . The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine. 2005; 23(40):4860-6. DOI: 10.1016/j.vaccine.2005.05.024. View

2.
Huleatt J, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A . Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2007; 26(2):201-14. DOI: 10.1016/j.vaccine.2007.10.062. View

3.
Wu J, Tu C, Yu X, Zhang M, Zhang N, Zhao M . Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: a powerful immunological approach. J Virol Methods. 2006; 139(1):50-60. DOI: 10.1016/j.jviromet.2006.09.017. View

4.
Pejoski D, Zeng W, Rockman S, Brown L, Jackson D . A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol. 2010; 88(5):605-11. DOI: 10.1038/icb.2010.15. View

5.
Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A . Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2010; 186(2):1022-31. DOI: 10.4049/jimmunol.0902147. View